The Types taxonomy of Antibody‑siRNA Drug Conjugates further refines market sizing by classifying products according to conjugation chemistry, antibody format, and siRNA payload architecture. Cleavable linkers (e.g., disulfide, enzymatic) dominate at 55 % of the type mix, offering controlled release of siRNA within target cells and thus higher clinical efficacy. Non‑cleavable linkers hold the remaining 45 %, favored for stability in circulation but requiring intracellular degradation mechanisms. Within antibody formats, full‑length IgG antibodies are prevalent (70 %) due to their long half‑life and Fc‑mediated effector functions, while fragment‑based formats (Fab, scFv) occupy 30 %, offering improved tissue penetration. Regarding siRNA payloads, single‑strand designs (antisense) represent 60 % of offerings, simplifying synthesis, whereas double‑strand duplexes account for 40 %, providing enhanced silencing potency. This multi‑dimensional type segmentation clarifies how each technical choice contributes to cost structures, scalability, and ultimately the overall market valuation.